Abstract-Intermittent high intensity ultrasound pulses with circulating contrast agent microbubbles can induce scattered cavitation caused myocardial microlesions of potential value for tissue reduction therapy. Here, computer-aided histological evaluation of the effective treated volume was implemented to optimize ultrasound pulse parameters, exposure duration, and contrast agent dose. Rats were treated with 1.5 MHz focused ultrasound bursts and Evans blue staining indicates lethal cardiomyocytic injury. Each heart was sectioned to provide samples covering the entire exposed myocardial volume. Both brightfield and fluorescence images were taken for up to 40 tissue sections. Tissue identification and microlesion detection were first done based on 2-D images to form microlesion masks containing the outline of the heart and the stained cell regions. Image registration was then performed on the microlesion masks to reconstruct a volume-based model according to the morphology of the heart. The therapeutic beam path was estimated from the 3-D stacked microlesions, and finally the total microlesion volume, here termed macrolesion, was characterized along the therapeutic beam axis. Radially symmetric fractional macrolesions were characterized via stepping disks of variable radius determined by the local distribution of microlesions. Treated groups showed significant macrolesions of a median volume of 87.3 μL, 2.7 mm radius, 4.8 mm length, and 14.0% lesion density compared to zero radius, length, and lesion density for sham. The proposed radially symmetric lesion model is a robust evaluation for myocardial cavitation-enabled therapy. Future work will include validating the proposed method with varying acoustic exposures and optimizing involved parameters to provide macrolesion characterization.
I. INTRODUCTION
H YPERTROPHIC cardiomyopathy (HCM), involving enlargement and hyperplasia of the myocardium, occurs in at least one out of 500 people. Sudden death is the most visible and unpredictable consequence of HCM, occurring without warning signs or symptoms. It has been reported that HCM is the most common cause of sudden death in young people, and is the most frequent cause of sudden death in US competitive athletes [1] . Although pharmacologic therapies have exhibited significant positive effects, there remain substantial undesired side effects, leaving approximately one third of patients as candidates for myocardial reduction [2] .
The definitive treatment for HCM is surgical myectomy [3] , which involves resection of a small portion of the interventricular septum (SP) at its base. Less-invasive alternatives have been explored using a variety of techniques, most commonly an endovascular procedure. However, the need for permanent pacing, the inability to address concomitant anatomic abnormalities and the uncertainty about the long-term effects of having caused substantial myocardial necrosis and scaring are undesirable. Other approaches such as thermal ablation [4] or histotripsy [5] reduce cardiac tissue by accumulating ultrasonic focal lesions.
For decades, ultrasonic bioeffects from microbubble inertial cavitation have been discussed for their therapeutic potentials [6] . Concurrent studies have investigated cavitation-induced microvessel and cell injuries [7] . A novel technique using contrast echocardiography using higher than diagnostic pressure amplitudes, named myocardial cavitation-enabled therapy (MCET), is hypothesized to induce a fractional macrolesion with sparse and histologically definable microlesions, which in turn shrink the diseased heart muscle without substantial scaring [8] .
Currently, therapeutic ultrasound has great potential in medicine as a noninvasive method to treat tumors, promote hemostasis, and treat other diseases due to its ability to penetrate deeply and deposit thermal or mechanical energy at a specific site with submillimeter accuracy. Various imaging modalities, including X-ray, computed tomography, magnetic resonance imaging, and ultrasound imaging, can provide precise targeting and therapy monitoring [9] .
Passive cavitation imaging has been demonstrated for potential use with continuous-wave high-intensity focused ultrasound thermal ablation [10] and for pulsed-wave ultrasound therapy insonations [11] . A system for microbubble-mediated sonothrombolysis utilizing therapy guidance and cavitation imaging has been developed [12] .
MCET is performed under the guidance of echocardiography. Ventricular premature complexes and blood pressure can provide temporal feedback [13] , while inertial cavitation mapping combined with anatomical imaging could delineate the spatial accumulation of cardiomyocytic response.
To evaluate the effectiveness of MCET treatment and modulate its treatment parameters, such as ultrasound amplitude, contrast dose, and treatment duration, an evaluation scheme is needed for characterizing microlesions. In previous studies, myocardial necrosis [8] , [14] was evaluated qualitatively by visual identification and scoring of Evans blue-stained cells in frozen histological slices [15] . However, visual scoring only yields a limited 1-D descriptor, i.e., scalar information of damaged cells assessed for each tissue slice, which is far from adequate to describe a comprehensive treatment outcome for tuning therapeutic inputs. For example, a qualitative score of 58,790 more than 23,560 helped making relative judgments about the optimum exposure parameters, but it gave no information about the amount of tissue reduction. Thus, an objective and quantitative scoring is needed to precisely determine treatment outcome and volume-based treatment. Spatial distribution evaluation is essential to ultimately develop a safe and effective therapeutic application.
Numerous methods have been devised for cellular and histological analysis. Molecular imaging, defined as the visual representation, characterization, and quantification of biological processes at cellular and subcellular levels, could be used to noninvasively detect and monitor cancer treatments [16] . It enables tumor localization, spatial visualization of specific molecular markers, and biological processes that influence tumor behavior and/or response to therapy [17] .
Regarding cellular microscopy, computational imaging provides multidimensional and quantitative image analysis, enabling mathematical modeling of cell biology. Employed process steps include image acquisition and preprocessing, registration, segmentation, volume rendering, etc. [18] . Image segmentation, including thresholding, region growing, and clustering, plays an important role in characterizing contents of medical images [19] . This paper describes a scheme for MCET characterization in acute preclinical studies. A computer-aided histological evaluation of MCET-induced macrolesions has been implemented to quantify treatment outcome. The point of the presented method is to provide the volumetric macrolesion determination to approximate the expected amount of tissue reduction, which was not available from the qualitative visual score. Two-dimensional brightfield and fluorescence images were evaluated by an algorithm, which automatically identified microlesions, and characterized the volume-oriented fractional macrolesion. Subsequently, this method can be applied to optimize ultrasound pulse parameters, exposure duration, and contrast agent dose for MCET treatment of HCM, which would require up to 25% vol-vol tissue reduction in some myocardial areas.
II. METHOD

A. Animal and Tissue Preparation
In concomitant research designed to optimize the timing of pulses for MCET, tissue samples were collected and prepared for histological evaluation. For this study, these samples were utilized for development of computer-aided evaluation. Briefly, in vivo animal procedures were conducted on 20 male SpragueDawley rats (Charles River, Wilmington, MA, USA) and five sham rats weighing 331 ± 33 g under the approval and guidance of the University Committee on Use and Care of Animals. All rats in the treated group were injected with Definity (Lantheus Medical Imaging, Inc., N. Billerica, MA) at a rate of 5 μL/kg/min. MCET was performed with 2 ms period 4 kHz PRF 1.5 MHz ultrasound burst of five cycle pulses at 4.0 MPa peak rarefactional pressure amplitude by use of a 1.9 cm diameter and 3.8 cm focus single element therapy transducer, triggered at one beat out of four heart beats. The therapeutic transducer was focused approximately 0.5 cm into the myocardium [13] . While the distance to the myocardium might change a few millimeters, the effect of choice of cardiac phase was studied in Miller et al. [21] and found to be not significant. Before being exposed to 5 minutes of therapy, all rats were injected with Evans blue, which has been proven to be a dependable stain for histological determination of cell necrosis [22] .
After being frozen in compound (Tissue-Tek, Sakura Finetek USA, Inc., Torrance, CA, USA) on dry ice, each heart was dissected to provide samples covering the entire exposed myocardial volume. Up to 40 sections, 10 μm thick, for each heart were cut every 200 μm into the sample to cover about 5 mm of the dissected portion of the heart. Two hundred micron spacing was set to avoid possible overlap of stained cardiomyocytes in adjacent sections and thoroughly sample the cardiac volume. However, it should be noted that some stained cells present in between sections were not actually observed, but assumed by extrapolation to have the same fractional lesion area over the 190 μm unsampled space.
B. Cardiomyocyte Scoring
Besides the proposed automatic characterization scheme, visual scoring and measurement of troponin I in plasma were performed to evaluate cardiomyocyte injuries. Visual scoring was based on Evans blue staining as described previously [13] . Troponin I was analyzed from plasma samples collected one day after euthanasia with an ELISA assay kit (Rat Cardiac Tn-I (ultra sensitivity), Life Diagnostics, Inc., West Chester, PA, USA). This cardiac enzyme is a sensitive indicator of cardiac injury in rodents [20] .
C. Microscope Image Acquisition
To enable computer-aided evaluation, both brightfield and fluorescence images were obtained for each tissue-section through a microscope camera system (SPOT Flex, Diagnostic Instruments, Inc., Sterling Heights, MI, USA) via fluorescent stereomicroscopy (Leica MZ FLIII, Leica Microscopy Systems, Ltd., Heerbrugg, Switzerland) with a high resolution and large field of view objective (Leica Plan APO 1.6×, Leica Microsystems, Ltd., Heerbrugg, Switzerland). The images were acquired as 16 bit 4,096 by 4,096 RGB, covering the entire tissue sections. One image set of treated myocardium at the approximate midpoint of the treated zone is shown in Fig. 1 microvascular hemorrhage, as shown in Fig. 1(a) . The damaged cardiomyocytes specifically appear fluorescent red in the relatively high contrast fluorescence image as shown in Fig. 1(b) . In contrast, normal heart tissue appears grayer in the brightfield image and darker in the fluorescence image. The therapeutic ultrasound beam path projected onto the 2-D image is estimated from the lesion cloud as shown in Fig. 1(b) . Brightfield images were taken using auto exposure to provide morphologic information and fluorescence images were taken using a constant exposure to provide constant and quantitative lesion contrast information.
D. Cardiomyocyte Modeling
An average cross-sectional area (A C ) for one cardiomyocyte sliced in a tissue section was estimated based on a mathemat- ical model, which then gave an approximation of the number of stained cells by dividing the total injured area by the estimated A C . A cardiac myocyte cell was geometrically modeled as an elliptic cylinder with cell dimensions summarized in Table I based on previous work [23] . The left ventricular wall comprises three strands of different longitudinal alignment: superficial (subepicardial) noted as S, middle noted as M, and deep (subendocardial) noted as D. The myocyte model approximated the superficial "layer" at an angle of 15°with respect to the long axis of the left ventricular inlet, occupying 25% of the wall thickness, the middle "layer" circumferentially arranged occupying 56% of the wall thickness, and the deep "layer" radiating longitudinally accounting for 19% of the wall thickness [24] . As illustrated in Fig. 2 , a slice plane intersects with layers of different cell orientation, resulting in variable cross-sectional areas. The average cross-sectional cell area A C is then given by
whereĀ S ,Ā M , andĀ D are average areas for the three layers: S, M, and D. P S , P M , and P D are the fractional volume percentages of each layer for the overall wall thickness, namely P S = 25% P M = 56%, and P D = 19%.
For the superficial layer, we assumed that the cutoff plane did not reach the edge so that the cross section was always strictly an ellipse. Thus, cross-sectional areas for superficial and deep layers were both considered as ellipses
For the middle layer, the intersection plane was always a rectangle with length equal to l, and width GH as depicted in Fig. 3 and determined by the orientation that the cutting plane 
and H (x 2 , y 2 ), if and only if x, y have real solutions. For a certain cutting angle θ, the maximum value that h could achieve is when the cutting line is tangent to the ellipse. Thus, h max is a function of θ. Thus, the length of the cutting edge GH, L GH , is a function of θ and h as follows:
We assume that θ and h are uniformly distributed variables within their range, i.e.
where p indicates the probability density function for p(θ) and p(h). The average cross-sectional areaĀ M in this case is
where
Finally, given the previous relationships, an average crosssectional area,Ā C , of 2,399 μm 2 can be computed. 
E. Lesion Characterization
To reduce computation complexity and save computation memory, the red channel, of all the data was first extracted. All the images were preprocessed to remove uneven illumination and zero padded ready for registration before feeding into the lesion characterization processing. Background illumination for both brightfield images and fluorescence images was estimated using a Gaussian low-pass filter [25] , which was then subtracted from the original images. The normalized images were processed following the steps shown in Fig. 4 . The main steps to characterize macrolesions include: 1) tissue detection; 2) microlesion detection; 3) image registration and 3-D stacking; 4) therapeutic beam estimation; and 5) macrolesion characterization.
Tissue detection and microlesion detection were first done based on 2-D images to form microlesion masks, which contain the morphologic information of the heart as well as stained cell regions. Image registration was then performed on microlesion masks to reconstruct a volume-based model according to the morphology of the heart. The therapeutic beam was estimated from the 3-D stacked microlesions, and finally a macrolesion was characterized along the therapeutic beam.
Step 1: Tissue detection. The main objective in this step is to segment the tissue portion based on morphologic information from brightfield images in order to constrain the subsequent characterization. Brightfield images [see Fig. 1(a) and (c)] were downsampled first to be segmented and then upsampled back after segmentation to decrease computational load. A threshold mask as shown in Fig. 5(b) and an edge-detected mask as shown in Fig. 5(c) were obtained simultaneously from a normalized brightfield image as the example shown in Fig. 5(a) , which was then fused together giving the tissue mask as shown in Fig. 5 
(d).
Step 2: Microlesion detection. Starting with an initial guess of 10% for the lesion density, two lesion masks were obtained from thresholding brightfield and fluorescence images. An automatic threshold, described later, for the fluorescence image was then determined from the statistics of pixel values within the mutual mask of the two lesion masks. An example of a lesion mask on top of a zoomed original brightfield image Fig. 6(a) is shown in Fig. 6(b) illustrating the morphologies of the detected lesions. Fig. 7 . Three-dimensional stacking of registered image masks allows for visualization of the employed 3-D model, where the red heart tissue surface outline is rendered as a result from step 1 (tissue detection), black marks symbolize downsampled microlesions detected in step 2, and the therapeutic ultrasound beam (blue line) is characterized from least square fitting of the microlesion cloud (see text for more details).
Step 3: Image registration and 3-D stacking. In order to process volume-based characterization, 2-D lesion masks were stacked to 3-D according to the information provided through neighboring brightfield images from the tissue slide stack, i.e., by means of the transformation information from rigid image registration. Stacking registered mask images allows for visualization of the employed 3-D model as shown in Fig. 7 , where the red contour is rendering the tissue edges as resulting from step 1, and black marks symbolize microlesions detected in step 2. The inner red oval shape is the exclusion representing the inner surface of the LV. For the purpose to visualize the overall effect of treatment, high-resolution image showing the detailed morphology of individual cell is unnecessary; thus, 32 times downsampled microlesions symbolized by black marks are displayed representing the trend of lesion density. However, the full resolution is used for characterization.
Step 4: Therapeutic beam estimation. The therapeutic beam vector shown as a blue line with an arrow in Fig. 7 was characterized by least square line fitting from the detected microlesions, excluding autofluorescing blood vessels and other nonmicrolesion microstructures, which were considered as noise.
Step 5: Macrolesion characterization. The stacked 3-D heart model was resliced along the therapeutic beam in 800-μm-thick steps. Note that the reslices here are not tissue-sections but slices perpendicular to the identified ultrasound beam. At each position along the beam axis, a disk was characterized as illustrated in Fig. 8(a) : each such slice was first populated with a 20-mm-diameter disk coaxial to the beam; each disk was then progressively reduced in size until a certain microlesion quantity was reached from a dynamic threshold, the criterion of which is explained below. Disks were characterized individually and then stacked together resulting in a final macrolesion as shown in Fig. 8(b) .
To determine the dynamic radius mentioned earlier, a dynamic percentage value of overall stained cells within a maximum slice volume is computed. The threshold is a piecewise function of total number of stained cells and is shown in Fig. 9 . Here Fig. 8 . Schematic diagram of the procedure for macrolesion characterization. The stacked 3-D heart model was resliced along the therapeutic beam in 800-μm-thick steps. At each position along the beam axis noted by a blue "x", a disk was characterized as illustrated in (a). Each disk started with a 20 mm diameter and coaxial to the beam and is graphically identified as the most outer dash circle; the disk diameter was then progressively reduced as the red arrow implies until a certain microlesion quantity was reached from a dynamic threshold (see Fig. 9 ). The resulting disk then characterizes the local macrolesion slice and is shown in yellow, surrounded by black solid line. The yellow cylinder-like volume as in (b), i.e., stacked disks, is defined as a macrolesion, characterized by a dynamic thresholding algorithm for counting enclosed microlesions for each disk step as illustrated in (a) (US: ultrasound). if
where N indicates the total number of stained cells detected, N 0 is a cutoff threshold for piecewise function, and T indicates the percentage threshold for radius selecting with a constant T 0 as a maximum. As illustrated in Fig. 9 , the example here sets N 0 = 30, T 0 = 95%.
The in vivo point spread function (PSF) of the therapeutic beam was characterized as a function of space by first sampling Fig. 10 . Characterized macrolesion visualization: the same as Fig. 7 , additionally the resulting volumetric macrolesion is shown as yellow disks along the therapeutic beam. Note that it did not include the distal cloud of microlesions. The inclusion criteria were chosen to reject volumes with less than 10% microlesion density. In a chronic study, we plan to explore what microlesion density will cause significant tissue reduction.
along the therapeutic beam interrogating coaxial cylinders of λ (1 mm) diameter and quarter λ length. Then, at the point of maximum axial lesion density, the lateral direction was sampled with coaxial rings of one-eighth λ width and quarter λ height. 
III. RESULTS
A. Lesion Visualization
A radially symmetric macrolesion was characterized via stepping disks of various radius determined by the local distribution of microlesions. An example is shown in Fig. 10 .
An example of a 3-D macrolesion intersecting with one of the original 2-D microscopy images is shown in Fig. 11 with a delineated boundary indicating macrolesion projection and tissue boundary characterized from brightfield tissue detection.
B. Group Comparison
As described in a concomitant study [13] , the treated group of rats was subdivided into three groups, with five rats in each Fig. 12 . Characterized features of macrolesions are compared to the measurement of troponin I in plasma samples taken one day after the treatment. The treated group was subdivided into three subgroups being treated at different time points of the cardiac cycle: R wave (RR, end diastole), R wave plus 1/3 of the R to R interval (RR/3, end systole), and R wave plus 2/3 of the R to R interval (2RR/3, mid-diastole).
group. They were treated at three different time points of the cardiac cycle: at the onset of R wave (RR, end diastole), at the R wave plus one-third of the R to R interval (RR/3, end systole) and at the R wave plus two thirds of RR (2RR/3, middiastole). Results for macrolesions characterized for all 20 rats are presented in Fig. 12 using boxplots. For each box, the central mark is the median, the edges of the box are the 25th and 75th percentiles, the whiskers extend to the most extreme data points not considered outliers, and outliers are plotted individually. The normal range was defined as greater than q 3 + 1.5 (q 3 − q 1 ) or smaller than q 1 − 1.5 (q 3 − q 1 ), where q 1 and q 3 are the 25th and 75th percentiles, respectively. Corresponding median values for treated groups are reported in Table II . The results show no significant variation between treated groups, which agree with the visual scoring results from the concomitant study.
The summarized results for the treated group of 15 rats compared to sham group show significant macrolesions with a median volume of 87.3 μL of 14.0% lesion density, 2.7 mm macrolesion radius, and 4.8 mm macrolesion length compared to zero lesion density, radius, and length for the sham group. This overall result was consistent with the measurements of troponin, which were also indicative of total cardiomyocyte necrosis.
C. Point Spread Function
The in vivo PSF of the therapeutic beam in terms of lesion density was characterized for one rat affected by an extreme long therapeutic path through the myocardium, as shown in Fig. 13 .
IV. DISCUSSION
This computer-aided histological evaluation appears to provide robust characterization of the macrolesion formed by the accumulation of microlesions based on the following considerations.
A. Therapeutic Beam Estimation
Occurrence of cavitation events induces the here observed damage to cardiac myocytes. It is expected that the lesion density would be uniform within the beam profile, where the acoustic pressure exceeds the cavitation threshold, assuming that the contrast agent in the myocardium is uniformly distributed. However, lesion uniformity could be disrupted by variable superthreshold acoustic pressures, which may injure more than one cell per cavitation event. Hence, we expect the lesion density trend of the microlesion to be dictated by the acoustic beam profile as well as processes involving motion of the myocardium. For example, breathing motion leads to smearing out the accumulation effect of the treatment, which then is not shaped strictly according to therapeutic beam. Thus, in turn, the therapeutic beam estimation is affected. A decreasing trend of the lesion density was observed along the axial direction, possibly due to acoustic attenuation caused by contrast agents in the LV. The lateral PSF profile was obtained at the maximum of the axial response, which was regarded as the volume of interest of the therapy. The in vivo PSF -6 dB lateral width of approximately 2.8 mm agrees reasonably with the 3.5 mm beam diameter of the therapy transducer as obtained from a free-field water tank calibration. The in vivo lateral beam width may be affected by aberration distortion of the sound wave propagating through overlying tissue layers, thus narrowing the beam diameter with pressure amplitudes above the threshold required for cavitation. Additionally, acoustic attenuation will reduce the in situ pressure amplitude and also narrow the beam cross section containing pressure amplitudes required for microlesion creation.
B. Cardiomyocyte Model Validation
A total of 160 manually selected cells according to the morphology appearing in brightfield images were taken an average to obtain estimation of area for a cell of 2,719 μm 2 versus 2,398 μm 2 from the theoretical geometric model. The 12% deviation of the estimation model from the selected estimation comes from bias on selecting large identifiable cells on the manual side and the variation from the cell orientation from the modeling side.
C. Cardiomyocyte Cell Scoring Validation
The Evans blue staining found in frozen sections, one day after therapy, identifies lethally injured cells resulting from microlesions [8] , [9] . Therefore, the total determination of the macrolesion as a fraction of the tissue volume provides a first approximation to the amount of tissue reduction expected from the treatment. The desired reduction would be about 20%, which could be expanded beyond the single focus treatment described here by moving the beam to provide the needed therapeutic reduction in larger (i.e., human) hearts. The simple visual scoring of the stained cells provides only a qualitative measure of the microlesion effect, particularly for high densities of microlesions seen in the treatments intended for therapeutic tissue reduction, which only approximate the more accurate image analysis values (see Fig. 14) . In addition, the qualitative visual scores fail to give a total fractional reduction throughout the treated volume, which is provided by the reconstruction of the volume and the macrolesion determination.
The cell identification scheme counts pixels rather than cells assuming an overall constant statistical mean multiplier for pixel to cell size conversion, by which the pixel counting and subsequent area to number of cells conversion is independent of the at times complicated cell morphology. The automatic scheme of stained cell identification seems reasonable compared to visual scoring as shown in Fig. 14 . The cases of large accumulations of stained cells were often difficult to score visually resulting in qualitative results rather than actual cell count. In contrast, the proposed computer-based characterization method is objective and quantitative and overcomes the limitation of large number of cells.
D. Lesion Characterization Criterion
The volume estimation of macrolesions considered local lesion density as well as total lesion number. Additionally, a dynamic radius cutoff criterion was used that depends on the number of the stained cells. Using a constant threshold for stained cell intensity would not affect the shape of a well-generated dense lesion due to the large number of microlesions in the macrolesion volume, but would affect a sparse macrolesion due to its low number density of microlesions. Thus, a dynamic threshold was introduced.
V. CONCLUSION
A computer-aided 3-D objective evaluation scheme has been developed to characterize macrolesions, including lesion size and lesion density, for MCET to reduce myocardial tissue, based on brightfield and fluorescence images as available in acute preclinical studies. The radially symmetric model employed to characterize macrolesion density is feasible for the study using a single focused beam. This methodology reduces visual scoring ambiguity and provides a volume oriented, quantitysensitive therapy evaluation. The significance of characterized macrolesion compared to sham group demonstrates that the evaluation scheme is robust against noise. Future implementations of MCET involve formulating a set of optimized treatment parameters to create a desired total volume reduction based on lesion density within the target volume. In particular, we are interested in the microlesion density and macrolesion size, as both determine the anticipated myocardium reduction. The proposed evaluation scheme could possibly assist quantifying other therapeutic applications resulting in sparse effects, such as drug delivery, gene therapy, and blood brain barrier opening.
